Finvest
CELC Biotechnology · Cancer drugs · Clinical stage · Launch watch · Thesis updated July 12, 2026

Gedatolisib is approved, now comes the launch

01 Running thesis

Approval changed the bet

Celcuity has moved from a pure trial story to an early commercial story. The key drug is gedatolisib, now branded REVTORPYK. The FDA approved it for adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation, after disease progression on or after at least one line of endocrine therapy.

The bull case is now clearer. VIKTORIA-1 data already supported the wild-type approval, and the mutant cohort also showed a statistically significant and clinically meaningful improvement in progression-free survival, meaning patients lived longer before the cancer got worse. Celcuity also hired and onboarded all oncology sales specialists, which lowers launch risk compared with a company still building its sales force.

The market size is the prize. Management said there are about 37,000 U.S. patients receiving second-line treatment for HR-positive, HER2-negative advanced breast cancer, and it estimates up to $2.5 billion of peak revenue for gedatolisib in that setting. That is a large number for a company that has not yet built a revenue base.

The bear case also changed. The biggest binary FDA risk for the first label is gone, but execution risk is now front and center. Celcuity must price the drug, win payer coverage, educate oncologists, manage safety concerns, and prove that demand shows up once supply is ready. The delayed late third quarter 2026 launch timing is a watch item because it tests how real the company's launch readiness was.

Jul 2026The FDA approved gedatolisib, now branded REVTORPYK, for PIK3CA wild-type HR-positive, HER2-negative advanced breast cancer. The story shifts from approval risk to launch execution.
May 2026Celcuity hired and onboarded its full oncology sales force and gave a peak revenue estimate of up to $2.5 billion for the second-line setting. It also added a subcutaneous formulation program and expanded VIKTORIA-2.
May 2026The PIK3CA mutant cohort of VIKTORIA-1 reported positive topline results, with a statistically significant and clinically meaningful improvement in progression-free survival. Celcuity plans to use the data for a supplemental NDA.
Jan 2026The FDA accepted the gedatolisib NDA for Priority Review and set a July 17, 2026 target action date. That gave investors a clear regulatory clock.
Jul 2025Celcuity raised about $286.5 million in net proceeds through equity and convertible note offerings. The financing extended the expected runway through 2027, but added debt risk.
Jul 2025The PIK3CA wild-type cohort of VIKTORIA-1 showed positive topline Phase 3 data, including a 76% reduction in the risk of disease progression or death for the triplet regimen versus fulvestrant alone.
May 2025Celcuity pushed the expected VIKTORIA-1 wild-type topline readout from the second quarter of 2025 to the third quarter of 2025. The delay moved the main de-risking event out by one quarter.
Nov 2024The company kept its cash runway through 2026 but moved the expected wild-type readout into late first quarter or second quarter 2025. The main thesis stayed tied to VIKTORIA-1.
02 Business model

One drug, funded by capital markets

Celcuity does not yet have an established product revenue stream. Its business is to develop gedatolisib, win approvals, then sell it through an oncology commercial team. Until sales begin, the company funds itself through stock sales, debt, and cash already on hand.

In July 2025, Celcuity raised about $286.5 million in net proceeds through public offerings of common stock and convertible senior notes. The company said its cash, short-term investments, and available borrowings should fund operations through 2027. That runway is important because the company is paying for trials and launch costs before meaningful revenue arrives.

The model breaks if doctors do not prescribe REVTORPYK at scale, if payers restrict access, or if side effects limit use. It also depends on the Pfizer license for gedatolisib and on outside partners for parts of development and commercialization support. Celcuity is more de-risked than it was before approval, but it is still highly concentrated in one asset.

03 Product portfolio

Gedatolisib carries the company

Growth engine

REVTORPYK, gedatolisib in PIK3CA wild-type breast cancer

This is the approved lead product and the first near-term revenue source. The label covers use with fulvestrant, with or without palbociclib, in a defined HR-positive, HER2-negative advanced breast cancer population.

Growth engine

VIKTORIA-1 PIK3CA mutant expansion

The mutant cohort reported positive topline Phase 3 results on May 1, 2026. Celcuity intends to submit a supplemental NDA using these data, which could expand the addressable patient group.

Option

VIKTORIA-2 first-line breast cancer program

This Phase 3 program tests gedatolisib earlier in treatment. Study 1 data are expected by the end of 2028, while the added endocrine-sensitive Study 2 pushes an important readout to 2030.

Option

Subcutaneous gedatolisib formulation

Celcuity is developing an under-the-skin version of gedatolisib and has filed its first patent application. The goal is to make longer-duration treatment easier in future indications.

Option

CELC-G-201 in metastatic castration-resistant prostate cancer

This Phase 1b/2 trial studies gedatolisib with darolutamide in mCRPC, a type of prostate cancer that keeps growing despite low testosterone. The company is exploring added doses before moving deeper into Phase 2.

Option

CELsignia diagnostic platform

This older companion diagnostic platform is not the main focus today. Celcuity has minimized work here so it can direct resources to gedatolisib.

04 Business segments

No revenue mix yet

Gedatolisib-focused operations100%growing fast
Other platform activities0%declining

Celcuity reports one integrated business focused on cancer therapy research, development, and commercialization. The mix below is not a revenue split because the company has not generated revenue and has no reportable product or geography segments.

05 Risk factors

What can still break

Launch fails to convert approval into sales

High impact · Medium odds

The first FDA approval removes one major risk, but it does not prove doctors will use the drug widely. Celcuity must teach oncologists where REVTORPYK fits, make supply available, and compete against established breast cancer drugs. A slow launch would raise doubts about the $2.5 billion peak revenue estimate.

We watchFirst U.S. launch timing, early prescription trends, and management comments on demand after launch.

Payers limit access

High impact · Medium odds

Cancer drugs can be approved but still face strict insurance rules. Celcuity has said it is in advanced payer discussions, but the exact pricing and access plan is still an open question. If insurers require many prior steps before covering REVTORPYK, uptake could be slower.

We watchPublished price, payer coverage policies, prior authorization rules, and patient assistance updates.

Safety profile narrows real-world use

High impact · Medium odds

The label and trial data include adverse events such as stomatitis and rash. If side effects lead to dose changes or treatment stops in real clinics, doctors may reserve the drug for fewer patients. This matters most because Celcuity needs strong adoption in a crowded oncology market.

We watchDiscontinuation rates, dose reduction rates, and physician feedback after the first months of launch.

Mutant-cohort filing disappoints

Medium impact · Medium odds

The PIK3CA mutant cohort has positive topline data, but Celcuity still needs to file a supplemental NDA and get FDA review. Detailed data could show a smaller benefit, tougher safety tradeoffs, or questions about the comparator. Any delay would slow the path to a wider label.

We watchThe sNDA filing date, FDA acceptance, review timeline, and detailed VIKTORIA-1 mutant cohort results.

Debt and cash burn tighten the runway

Medium impact · Medium odds

Celcuity raised about $286.5 million in July 2025, including convertible notes, and says cash should last through 2027. That helps, but launch spending and ongoing Phase 3 trials are costly. The $201.25 million of convertible notes add debt risk if sales ramp slowly.

We watchQuarterly cash balance, operating cash burn, debt terms, and any new financing.
06 Quick answers

In one breath

What does Celcuity sell?

Celcuity is preparing to sell REVTORPYK, the brand name for gedatolisib. It is an FDA-approved breast cancer drug for a defined HR-positive, HER2-negative advanced breast cancer population.

Why is the stock still risky after FDA approval?

Approval lowers regulatory risk for the first label, but it does not guarantee strong sales. The company still needs payer coverage, doctor adoption, safe real-world use, and a clean launch.

What is the next big Celcuity catalyst?

The next key items are the U.S. commercial launch and the planned supplemental NDA for PIK3CA mutant patients. Longer term, VIKTORIA-2 could move gedatolisib into earlier breast cancer treatment, but those data are years away.